BIOGEN AVONEX SALES, ORPHAN PROTECTION CREATE JULY SIZZLE; STOCK UP 6-1/4
Executive SummaryBiogen rebounded in July after two months of decline as the launch of Avonex for multiple sclerosis and the drug's orphan exclusivity keeping a second competitor from Berlex off the market helped Biogen sizzle
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.